P213 High baseline serum IL-6 predicts increased sarilumab treatment response for patient reported symptoms and health-related quality of life among RA patients with inadequate response to MTX
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa111.208
Abstract: IL-6, a key cytokine in rheumatoid arthritis (RA) pathogenesis, is elevated in patient serum and synovial fluid. However, the impact of baseline IL-6 levels on patient-reported RA symptoms and health-related quality of life (HRQoL) following… read more here.
Keywords: patient reported; regeneron pharmacueticals; regeneron; mtx ... See more keywords
FRI0120 HIGH LEVELS OF INTERLEUKIN-6 (IL-6) IN RA PATIENTS ARE ASSOCIATED WITH GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES (PROS) FOR SARILUMAB COMPARED WITH ADALIMUMAB
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.3294
Abstract: Background Increased levels of cytokines, including interleukin-6 (IL-6), reflect inflammation and are predictive of therapeutic responses in patients with RA. IL-6 has been implicated in fatigue, pain and depression in RA but a formal association… read more here.
Keywords: high levels; treatment; regeneron pharmaceuticals; regeneron ... See more keywords
FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2181
Abstract: Background: Evaluation of early response to rheumatoid arthritis (RA) therapy at 12 weeks after initiation is recommended in treatment guidelines. C-reactive protein (CRP) response at 12 weeks on therapy may indicate favorable longer-term patient-reported outcomes… read more here.
Keywords: regeneron pharmaceuticals; regeneron; monarch; sanofi genzyme ... See more keywords